InMode (NASDAQ:INMD) Reaches New 52-Week Low – Here’s Why

InMode Ltd. (NASDAQ:INMD – Get Free Report)’s share price reached a new 52-week low during trading on Thursday. The stock traded as low as $12.61 and last traded at $12.6950, with a volume of 61,684 shares changing hands. The stock had previously closed at $12.88.

Analyst Ratings Changes

INMD has been the subject of a number of research reports. Weiss Ratings upgraded InMode from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Robert W. Baird reduced their target price on shares of InMode from $17.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, InMode presently has an average rating of “Hold” and an average target price of $16.33.

View Our Latest Analysis on INMD

InMode Stock Performance

The firm has a 50 day moving average price of $13.90 and a two-hundred day moving average price of $14.21. The firm has a market capitalization of $713.90 million, a P/E ratio of 10.69 and a beta of 1.98.

InMode (NASDAQ:INMD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 11th. The healthcare company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.05. InMode had a return on equity of 11.55% and a net margin of 19.94%. The firm had revenue of $92.14 million for the quarter, compared to the consensus estimate of $91.58 million. During the same quarter in the previous year, the company earned $0.38 EPS. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year.

Institutional Trading of InMode

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in shares of InMode by 6.1% during the 1st quarter. Renaissance Technologies LLC now owns 2,586,218 shares of the healthcare company’s stock valued at $35,379,000 after buying an additional 149,800 shares during the period. Steel Partners Holdings L.P. lifted its holdings in InMode by 154.8% in the 1st quarter. Steel Partners Holdings L.P. now owns 1,795,361 shares of the healthcare company’s stock worth $24,561,000 after purchasing an additional 1,090,697 shares during the last quarter. Systematic Financial Management LP boosted its holdings in shares of InMode by 6.7% during the 1st quarter. Systematic Financial Management LP now owns 1,154,457 shares of the healthcare company’s stock worth $15,793,000 after buying an additional 72,041 shares during the period. Janus Henderson Group PLC boosted its holdings in InMode by 5.0% during the first quarter. Janus Henderson Group PLC now owns 932,132 shares of the healthcare company’s stock valued at $12,752,000 after acquiring an additional 44,575 shares during the period. Finally, Lind Value II ApS increased its position in InMode by 16.1% in the 3rd quarter. Lind Value II ApS now owns 428,365 shares of the healthcare company’s stock worth $6,070,000 after buying an additional 59,478 shares during the period. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Company Profile

(Get Free Report)

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.

Further Reading

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.